News Ascletis says oral acne drug shows "exceptional efficacy" Phase 3 results for Ascletis' novel acne candidate have set up filings in China and bode well for a similar drug being developed by Sagimet in the US.
News Apogee Therapeutics upsizes its IPO to $300m In a small sign of a possible improvement in the sluggish biotech initial public offering (IPO) market, Apogee Therapeutics has said it expects gross proceeds of $300 mill
News NICE backs UCB drug as first uncontrolled gMG therapy UCB's Rystiggo can be used by the NHS as a backup treatment for people with the rare autoimmune and neuromuscular disease gMG, says NICE.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.